FGFR3 testing in bladder cancer

This session will explore the FGFR genomic alterations and their role in cancer, with a focus on the clinical utility of FGFR3 in bladder cancer. Furthermore, Dr. Michael Hubank will explore the bladder cancer patient diagnostic journey, and the technical challenges and considerations in FGFR3 and bladder cancer testing, including considerations on biopsy, test selection, sample quality, and interpretation of results. This event will include a Q&A session at the end, where you can ask Dr. Hubank your questions on this topic.

This Lab Talk took place on 5th June 2024.

Watch the recording now!

Dr. Michael Hubank has worked in Genomics for over 20 years. Following a PhD at UCL, he worked at the University of Sussex and Yale University before returning to the UCL Institute of Child Health in 2000 to found and run UCL Genomics. In 2016 he moved into clinical diagnostics at the Royal Marsden Hospital, London, to lead a translational laboratory focused on the development and clinical application of genomic assays for cancer diagnostics. Since 2018 he has been Scientific Director at the NHS England North Thames Genomic Laboratory Hub.

He is a joint investigator on several research projects using multiomic profiling for optimising personalised diagnostics and treatments for childhood cancer patients. He has a strong focus on developing and applying genomic assays, and a particular interest in moving circulating biomarkers into standard of care testing.

^{Approval code: EM-163967}